Академический Документы
Профессиональный Документы
Культура Документы
July 2, 2008
Tomoyasu Toyoda
President, Pharmaceuticals Company
Ajinomoto Co., Inc.
Copyright © 2008 Ajinomoto Co., Inc. All rights reserved.
Page 2
Contents
zManagement Philosophy
9 Contribute to health and a better quality of life for the people of
the world through unique pharmaceuticals that only the
Ajinomoto Group can develop
zManagement Vision
9 Aim to become the number one specialty pharmaceuticals
supplier based on TNC (Total Nutrition Care*) and a focus on
large-scale, field-specialized drugs
*TNC = Total Nutrition Care. TNC means to recognize nutritional therapy as the base of every therapy and direct
diagnosis (and preventive care), care, prevention of recurrence and improvement of prognosis performed by
medical practitioners toward improvement of QOL of both patients and presymptomatic patients.
Pharmaceuticals Business:
Review of FY 2005 – 2007
(¥ billion)
FY 2007
FY 2004 FY 2005 FY 2006 FY 2007 Initial targets
Main Products
Products Sold by Ajinomoto : LIVACT, SOLITA-T, ELENTAL, etc.
Products Sold through Business Tie-ups : ATELEC, ACTONEL, FASTIC, etc.
Copyright © 2008 Ajinomoto Co., Inc. All rights reserved.
Page 5
Field Name Indication Note Phase I Phase II Phase III NDA filed
Strong Gastro-
Liver Dialysis
fields intestinal
TNC
食道
Esophagus
胃
Stomach
Liver
肝臓 膵臓
Pancreas
IBD : 33.0
ELENTAL 7.2 (AJP)
5-ASA preparation 18.0
Steroids 1.5
Immunoregulatory drugs 2.0 Small
小腸intestine
Remicade 4.0
Other 0.3
Large
大腸 Colonoscopy : 5.0
intestine
Blind gut
NIFLEC 2.5 (AJP)
盲腸
Lactobacillus preparation : 13.0 MAGCOROL P 1.0
Enteronon-R (AJP) Anus
肛門 MUBEN 1.0
Hemorrhoidal diseases : 13.0 Other 0.5
Proctosedyl (AJP)Copyright © 2008 Ajinomoto Co., Inc. All rights reserved.
Page 10
IBD
Both are incurable diseases that cause ulcers
in the gastrointestinal tract (There is a patient registration system),
and IBD patients have been increasing steadily since 1970s in Japan
Patients
Crohn's Disease Patients Ulcerative colitis
AJG501 (Salofalk )
■Drug characteristics • Once daily dosing ■Drug characteristics • Dosings 3 times per day
• 1.5-3.0g per dose • 2-3 tablets per dosing
• Formulation: granules • Formulation: tablets
■ Indication: ulcerative colitis Diameter: 9.6mm
Thickness: 4.6mm
¾ 80% of physicians prefer reduced dosing
frequency ■ Indication: ulcerative colitis and Crohn’s disease
(Aminosalicylic acid Pentasa is a basic treatment in
¾ Over 60% of physicians prefer granules
Japan.)
⇒Aiming for over 30% prescription share
■Sales: ¥17.0 billion (NHI price basis)
■Status overseas (once daily dosing) ■ Share of prescriptions: Over 75%
¾ Germany: NDA filed (Approval expected in 2008)
¾ UK: Approved
¾ USA: NDA filed (Approval expected in 2008)
Establishment of
AJINOMOTO NUTRITION FOODS Co., Ltd.
New Company Profile
Company name AJINOMOTO NUTRITION FOODS Co., Ltd.
Head office 1-1, Irifune 2-chome, Chuo-ku, Tokyo
Established April 1, 2008
20.0
Reinforce Ajinomoto Co., Inc.’s ongoing
TNC activities and proposals for nutritional
10.0 management by collaboration between
Ajinomoto Pharma Co., Ltd. (covering
0.0 mainly hospitals/clinics) and AJINOMOTO
FY 2006 FY 2007 FY 2008 FY 2009 target FY 2010 target NUTRITION FOODS Co., Ltd. (covering
forecast mainly nursing homes and direct sales to
home care patients).
Establishment of AJINOMOTO NUTRITION FOODS Co., Ltd.
Core products
MEDIF bag
MEDIF PUSH CARE
MEDIF AMINO PLUS
PEMVest
MEDIF
IMPACT
Copyright © 2008 Ajinomoto Co., Inc. All rights reserved.
Page 14
Development System Me
eti
The “medical foods section” was clin ng ne
ica eds
l si
established in the Pharmaceutical tes in
Research Laboratories as of April 1,
2008 as part of efforts to strengthen the
development system for enteral nutrition.
Copyright © 2008 Ajinomoto Co., Inc. All rights reserved.
Page 15
0.0 0.0
FY 2001 FY 2002 FY 2003 FY 2004 FY 2005 FY 2006 FY 2007
40.0
10.0
20.0 5.0
(OP margin) (15.1%) (18.9%) (17.8%) (16.0%) (14.4%) (20.0%)